Cancer therapy with the T cell growth factor interleukin (IL)-2 is limited by low response rates and toxicity. Multiple protein engineering strategies have attempted to improve IL-2 therapy, typically through enhanced IL-2 receptor (IL-2R) binding. Intriguingly, Mo et al. show that an IL-2R partial agonist may dramatically improve IL-2 responses by altering T cell differentiation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tips.2021.11.003 | DOI Listing |
Publication Analysis
Top Keywords
improve il-2
8
engineering cell
4
cell memory
4
memory antitumor
4
antitumor immunity
4
immunity cancer
4
cancer therapy
4
therapy cell
4
cell growth
4
growth factor
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!